<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401280</url>
  </required_header>
  <id_info>
    <org_study_id>WSL treatment</org_study_id>
    <nct_id>NCT04401280</nct_id>
  </id_info>
  <brief_title>Bioactive Glass in the Treatment of Enamel White Spot Lesions</brief_title>
  <official_title>Effectiveness of Two Types of Bioactive Glass in the Treatment of Enamel White Spot Lesions : A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rania Salah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of this study is to evaluate the effectiveness of BiominF® and Novamin® in comparison
      to Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) in the treatment of enamel
      white spot lesions
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>White spot lesion dimensions (T0)</measure>
    <time_frame>Baseline</time_frame>
    <description>Quantified using computer-assisted analysis based on digital intraoral photographs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in White spot lesion dimensions (T1)</measure>
    <time_frame>1 month</time_frame>
    <description>Quantified using computer-assisted analysis based on digital intraoral photographs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in White spot lesion dimensions (T2)</measure>
    <time_frame>3 months</time_frame>
    <description>Quantified using computer-assisted analysis based on digital intraoral photographs</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>White Spot Lesion of Tooth</condition>
  <arm_group>
    <arm_group_label>BiominF®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novamin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC Tooth Mousse</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BiominF</intervention_name>
    <description>in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached</description>
    <arm_group_label>BiominF®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novamin</intervention_name>
    <description>in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached</description>
    <arm_group_label>Novamin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC tooth mousse</intervention_name>
    <description>applied in accordance with the manufacturer's specifications</description>
    <arm_group_label>GC Tooth Mousse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not less than 1 white spot lesion on the labial surface of teeth in the anterior
             region with code 2 International Caries Detection and Assessment System II (ICDAS-II)
             or less

          -  Absence of any active periodontal disease.

          -  Written informed consent

        Exclusion Criteria:

          -  Known hypersensitivity/allergy to study products and/or materials used

          -  teeth having deep carious lesions or extensive restorations

          -  Unwillingness to be randomly assigned to 1 of the 3 treatment groups

          -  Advanced periodontal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rania Abdelrahman, bachelor</last_name>
    <phone>1220222937</phone>
    <phone_ext>+20</phone_ext>
    <email>Raniasalah770@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Dentistry</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Esraa Ghazy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Rania Salah</investigator_full_name>
    <investigator_title>Clinical instructor and Principal investigator at conservative dentistry department</investigator_title>
  </responsible_party>
  <keyword>Bioactive glass</keyword>
  <keyword>CPP-ACP</keyword>
  <keyword>Remineralization</keyword>
  <keyword>White spot lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

